☆ 4.3 Article

Haemostatic effect of adding tranexamic acid to emicizumab prophylaxis in severe haemophilia A: A preclinical study

HAEMOPHILIA (2021)

Related references

Note: Only part of the references are listed.

Review Biotechnology & Applied Microbiology

Bispecific antibodies for the treatment of hemophilia A

Midori Shima

Summary: Emicizumab is a bispecific antibody with the function of FVIIIa cofactor regardless of the presence of FVIII inhibitors. Long-term data from phase 1/2 and phase 3 studies have been accumulated. The use of Emicizumab is a definite therapeutic option for patients with a persistent inhibitor, although concerns about BPAs-associated thromboembolic/TMA events exist. For non-inhibitor patients, especially pediatric patients, Emicizumab prophylaxis can be considered.

EXPERT OPINION ON BIOLOGICAL THERAPY (2022)

Add to Collection

Article Pharmacology & Pharmacy

Safety evaluation of emicizumab prophylaxis in individuals with haemophilia A

Cassandra P. Wang et al.

Summary: Emicizumab is an effective alternative to prophylaxis with factor VIII replacement in individuals with hemophilia A, showing improved outcomes in reducing bleeding events. Despite a few cases of thrombotic microangiopathy and thrombotic events seen in the HAVEN 1 trial, overall, Emicizumab has an excellent safety profile with minimal side effects.

EXPERT OPINION ON DRUG SAFETY (2021)

Add to Collection

Article Hematology

The effect of emicizumab prophylaxis on long-term, self-reported physical health in persons with haemophilia A without factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studies

Mark W. Skinner et al.

Summary: The study demonstrated that emicizumab prophylaxis in severe HA patients without FVIII inhibitors led to sustained and significant improvements in Haem-A-QoL PH, especially in subgroups with poorer HRQoL prior to treatment initiation. No significant changes were observed in EQ-5D-5L scores over time.

HAEMOPHILIA (2021)

Add to Collection

Article Orthopedics

Tranexamic acid given into wound reduces postoperative drainage, blood loss, and hospital stay in spinal surgeries: a meta-analysis

Shangyi Hui et al.

Summary: This meta-analysis aimed to investigate the effectiveness of tTXA in reducing postoperative drainage, hidden blood loss, and hospital stay duration in spine surgeries. The results showed significantly reduced postoperative drainage output and duration, perioperative hidden blood loss, and length of hospital stay in the tTXA group.

JOURNAL OF ORTHOPAEDIC SURGERY AND RESEARCH (2021)

Add to Collection

Review Hematology

Asymptomatic Joint Bleeding and Joint Health in Hemophilia: A Review of Variables, Methods, and Biomarkers

Richard Gooding et al.

Summary: Joint health is crucial for the quality of life in patients with hemophilia, and early prevention and treatment of joint abnormalities are key. Early and sustained prophylaxis with factor replacements can improve long-term joint outcomes, but some patients may develop arthropathy despite good bleeding outcomes. Imaging techniques and biomarkers can detect early joint damage, highlighting the importance of establishing relevant tools and treatment methods.

JOURNAL OF BLOOD MEDICINE (2021)

Add to Collection

Article Hematology

Hemostatic effect of tranexamic acid combined with factor VIII concentrate in prophylactic setting in severe hemophilia A: A preclinical study

Maissa Janbain et al.

JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2020)

Add to Collection

Article Hematology

Effect of Tranexamic Acid on Coagulation and Fibrin Clot Properties in Children Undergoing Craniofacial Surgery

Christian Fenger-Eriksen et al.

THROMBOSIS AND HAEMOSTASIS (2020)

Add to Collection

Article Hematology

A hemophilia A mouse model for the in vivo assessment of emicizumab function

Stephen Ferriere et al.

BLOOD (2020)

Add to Collection

Review Hematology

Management of bleeding and invasive procedures in haemophilia A patients with inhibitor treated with emicizumab (Hemlibra®): Proposals from the French network on inherited bleeding disorders (MHEMO), the French Reference Centre on Haemophilia, in collaboration with the French Working Group on Perioperative Haemostasis (GIHP)

Sophie Susen et al.

HAEMOPHILIA (2019)

Add to Collection

Article Orthopedics

Tranexamic acid may benefit patients undergoing total hip/knee arthroplasty because of haemophilia

Ze Yu Huang et al.

BMC MUSCULOSKELETAL DISORDERS (2019)

Add to Collection

Article Hematology

Design and characterization of an APC-specific serpin for the treatment of hemophilia

Stephanie G. I. Polderdijk et al.

BLOOD (2017)

Add to Collection

Article Medicine, General & Internal

Emicizumab Prophylaxis in Hemophilia A with Inhibitors

Johannes Oldenburg et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Add to Collection

Article Hematology

An in-vitro assessment of tranexamic acid as an adjunct to rFVIII or rFVIIa treatment in haemophilia A

Catherine J. Rea et al.

ANNALS OF HEMATOLOGY (2014)

Add to Collection

Article Hematology

Combined treatment with APCC (FEIBA®) and tranexamic acid in patients with haemophilia A with inhibitors and in patients with acquired haemophilia A - a two-centre experience

M. Holmstrom et al.

HAEMOPHILIA (2012)

Add to Collection

Article Hematology

Evaluation of the overall haemostatic effect of recombinant factor VIIa by measuring thrombin generation and stability of fibrin clots

Y. Dargaud et al.

HAEMOPHILIA (2011)

Add to Collection

Article Hematology

Towards a standardization of the murine tail bleeding model

T. K. Greene et al.

JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2010)

Add to Collection

Article Hematology

Monitoring platelet dependent thrombin generation in mice

Yesim Dargaud et al.

THROMBOSIS RESEARCH (2010)

Add to Collection

Review Hematology

Thrombin generation and fibrin clot structure

Alisa S. Wolberg

BLOOD REVIEWS (2007)

Add to Collection

Review Pharmacology & Pharmacy

Pharmacological strategies to decrease transfusion requirements in patients undergoing surgery

RJ Porte et al.

DRUGS (2002)

Add to Collection

© Peeref 2019-2024. All rights reserved.